Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 284 results for coronavirus

  1. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.

  2. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST34)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.

  3. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

  4. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  5. Perioperative care in adults (NG180)

    This guideline covers care for adults (aged 18 and over) having elective or emergency surgery, including dental surgery. It covers all phases of perioperative care, from the time people are booked for surgery until they are discharged afterward. The guideline includes recommendations on preparing for surgery, keeping people safe during surgery and pain relief during recovery.

  6. COVID-19 rapid guideline: critical care in adults (NG159)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  7. COVID-19 rapid guideline: acute myocardial injury (NG171)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  8. RespiraSense for continuously monitoring respiratory rate (MIB299)

    NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .

  9. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  10. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  11. FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome (MIB281)

    NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .

  12. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

    27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  13. Policies, procedures and reports

    Policies, procedures, reports and codes of practice relating to the governance of NICE.

  14. Guidance, NICE advice and quality standards in development

    View a complete list of all our guidance, NICE advice and quality standards currently in development

  15. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.